A redox-responsive nanosystem to suppress chemoresistant lung cancer through targeting STAT3
Journal of Controlled Release · 2023
DOI: 10.1016/j.jconrel.2023.09.044 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Qiyi Feng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Precision Medicine Center, Huaxi MR Research Center (HMRRC), Frontiers Science Center for Disease…. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Cancer stem cells (CSCs) have been demonstrated to be involved in tumor initiation and relapse, and the presence of CSCs in the tumor tissue often leads to therapeutic failure. BBI608 has been identified to eliminate CSCs by inhibiting signal transducer and activator of transcription 3 (STAT3). In this study, we confirm that BBI608 can efficiently suppress the proliferation and migration of non-small cell lung cancer (NSCLC) cells, and specifically kill the stemness-high population in chemoresistant NSCLC cells. To improve its bioavailability and tumor accumulation, BBI608 is successfully encapsulated into redox-responsive PEGylated branched N-(2-hydroxypropyl) methacrylamide (HPMA)-deoxy cholic acid (DA) polymeric nanoparticles (BBI608-SS-NPs). The BBI608-SS-NPs can release the drug in response to high concentrations of intracellular glutathione, and exhibit cytotoxicity against lung cancer cells and CSCs comparable to the free drug BBI608. Furthermore, the BBI608-SS-NPs preferentially accumulate in tumor sites, resulting in a superior anti-tumor efficacy in both cisplatin-resistant cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) models of NSCLC. Mechanistic studies demonstrate that BBI608-SS-NPs not only directly inhibit the downstream genes of the STAT3 pathway, but also indirectly inhibit the Wnt pathway. Overall, this stimuli-responsive polymeric nanoformulation of BBI608 shows great potential in the treatment of chemoresistant NSCLC by targeting CSCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Precision Medicine Center, Huaxi MR Research Center (HMRRC), Frontiers Science Center for Disease-Related Molecular Network, National Clinical Research Center for Geri…
Zitieren
APA
Feng, Q., Chen, J., Huang, J., Li, X., Liu, X., Xiao, C., Zheng, X., Chen, X., Li, J., Gu, Z., Luo, K., Xiao, K., & Li, W. (2023). A redox-responsive nanosystem to suppress chemoresistant lung cancer through targeting STAT3. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.09.044
Vancouver
Feng Q, Chen J, Huang J, Li X, Liu X, Xiao C, et al. A redox-responsive nanosystem to suppress chemoresistant lung cancer through targeting STAT3. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.09.044
BibTeX
@article{Feng2023,
author = {Feng, Qiyi and Chen, Jie and Huang, Jinxing and Li, Xiaojie and Liu, Xinyi and Xiao, Chunxiu and Zheng, Xiuli and Chen, Xuanming and Li, Jue and Gu, Zhongwei and Luo, Kui and Xiao, Kai and Li, Weimin},
title = {A redox-responsive nanosystem to suppress chemoresistant lung cancer through targeting STAT3},
journal = {Journal of Controlled Release},
year = {2023},
doi = {10.1016/j.jconrel.2023.09.044}
}
EUVIMED